Nectin Therapeutics

Developing immuno-oncology and ADC breakthrough therapies

Jerusalem, Israel · Founded 2017 · $46.4M raised

Headquarters
Jerusalem
Founded
2017
Business Model
B2B
Total Funding
$46.4M
Last Round
$10.0M Series AJan 2024
Rounds
4

About

The Company, established in 2017 is based on seminal research conducted at the Hebrew University of Jerusalem and the University of Rijeka. Our technology addresses major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies (mAbs) and antibody-drug-conjugates (ADCs). In late 2022 we launched phase 1 of a clinical trial for NTX1088, our first-in-class anti-PVR targeted immunotherapy for the treatment of patients with advanced solid tumors together with MD Anderson and entered into a clinical trial collaboration agreement with MSD (Merck).

Summary

Nectin Therapeutics is a Biotech company based in Jerusalem, Israel, founded in 2017. It has raised $46.4M in total across 4 rounds, most recently a $10.0M Series A round in Jan 2024. Investors include aMoon, Cancer Focus Fund and Guangzhou Sino-Israel Bio-Industry Investment Fund.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AJan 2024
$10.0M

Sign up to see all 4 rounds

Seed through Series A — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Nectin Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/nectin-therapeutics"><img src="https://indexed.vc/api/badge/company/nectin-therapeutics" alt="Nectin Therapeutics on Indexed.vc" width="260" height="76" /></a>